NTRK1 and neoplasm: For example, neurotrophin tyrosine receptor kinase (NTRK) gene fusions (NTRK1, NTRK2, or NTRK3) are oncogenic drivers in various tumor types18 that can be targeted by recently developed TRK inhibitors19,20 and ESR1 fusions were resistant mechanism of endocrine therapy in HR-positive BC21.